Cargando…

Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity

AIM: Multiple drug intolerance syndrome (MDIS) is a unique clinical entity distinct from other drug hypersensitivity syndromes. The aim of this review was to critically appraise the various aspects of MDIS. METHODS: A review was conducted to search for the causes, mechanism, clinical features, and m...

Descripción completa

Detalles Bibliográficos
Autores principales: Behera, Sapan K., Das, Saibal, Chengappa, Kavadichanda G., Xavier, Alphienes S., Selvarajan, Sandhiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011677/
https://www.ncbi.nlm.nih.gov/pubmed/30417793
http://dx.doi.org/10.2174/1574884713666181112125714
_version_ 1783496109788758016
author Behera, Sapan K.
Das, Saibal
Chengappa, Kavadichanda G.
Xavier, Alphienes S.
Selvarajan, Sandhiya
author_facet Behera, Sapan K.
Das, Saibal
Chengappa, Kavadichanda G.
Xavier, Alphienes S.
Selvarajan, Sandhiya
author_sort Behera, Sapan K.
collection PubMed
description AIM: Multiple drug intolerance syndrome (MDIS) is a unique clinical entity distinct from other drug hypersensitivity syndromes. The aim of this review was to critically appraise the various aspects of MDIS. METHODS: A review was conducted to search for the causes, mechanism, clinical features, and management of MDIS. RESULTS: The most common cause of MDIS is antibiotics followed by non-steroidal anti-inflammatory drugs (NSAIDs). Although some non-specific immunological mechanisms are involved, the immunological tests for MDIS are negative. Rashes, gastrointestinal reflux, headache, cough, muscle ache, fever, dermatitis, hypertension, and psychiatric symptoms are the usual manifestations. Treatment is mostly symptomatic with the withdrawal of the offending drug. Drug re-challenges and desensitization may be required for the management of this syndrome. CONCLUSION: MDIS occurs by a nonimmune mechanism which requires a prompt withdrawal of the offending drug(s), and in some cases may require drug re-challenge and desensitization.
format Online
Article
Text
id pubmed-7011677
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-70116772020-03-06 Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity Behera, Sapan K. Das, Saibal Chengappa, Kavadichanda G. Xavier, Alphienes S. Selvarajan, Sandhiya Curr Clin Pharmacol Article AIM: Multiple drug intolerance syndrome (MDIS) is a unique clinical entity distinct from other drug hypersensitivity syndromes. The aim of this review was to critically appraise the various aspects of MDIS. METHODS: A review was conducted to search for the causes, mechanism, clinical features, and management of MDIS. RESULTS: The most common cause of MDIS is antibiotics followed by non-steroidal anti-inflammatory drugs (NSAIDs). Although some non-specific immunological mechanisms are involved, the immunological tests for MDIS are negative. Rashes, gastrointestinal reflux, headache, cough, muscle ache, fever, dermatitis, hypertension, and psychiatric symptoms are the usual manifestations. Treatment is mostly symptomatic with the withdrawal of the offending drug. Drug re-challenges and desensitization may be required for the management of this syndrome. CONCLUSION: MDIS occurs by a nonimmune mechanism which requires a prompt withdrawal of the offending drug(s), and in some cases may require drug re-challenge and desensitization. Bentham Science Publishers 2019-12 2019-12 /pmc/articles/PMC7011677/ /pubmed/30417793 http://dx.doi.org/10.2174/1574884713666181112125714 Text en © 2019 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Behera, Sapan K.
Das, Saibal
Chengappa, Kavadichanda G.
Xavier, Alphienes S.
Selvarajan, Sandhiya
Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity
title Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity
title_full Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity
title_fullStr Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity
title_full_unstemmed Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity
title_short Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity
title_sort multiple drug intolerance syndrome: an underreported distinct clinical entity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011677/
https://www.ncbi.nlm.nih.gov/pubmed/30417793
http://dx.doi.org/10.2174/1574884713666181112125714
work_keys_str_mv AT beherasapank multipledrugintolerancesyndromeanunderreporteddistinctclinicalentity
AT dassaibal multipledrugintolerancesyndromeanunderreporteddistinctclinicalentity
AT chengappakavadichandag multipledrugintolerancesyndromeanunderreporteddistinctclinicalentity
AT xavieralphieness multipledrugintolerancesyndromeanunderreporteddistinctclinicalentity
AT selvarajansandhiya multipledrugintolerancesyndromeanunderreporteddistinctclinicalentity